MYCN-targeting vaccines and immunotherapeutics.
Hum Vaccin Immunother. 2016 Sep;12(9):2257-8
Authors: Schramm A, Lode H
Abstract Amplification and concomitant overexpression of the MYCN oncogene is a frequent event in many malignancies including the childhood tumors, neuroblastoma and medulloblastoma. MYCN is only expressed in a defined time frame during early developmental processes, (1) which is beneficial for approaches combatting tumor-specific MYCN.